Competing risks of extended adjuvant aromatase inhibitors
Mené sur 3 966 patientes atteintes d'un cancer du sein HR+ de stade I-IIIA après la ménopause, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie à 5 ans, et la toxicité du létrozole dispensé après un traitement par inhibiteur de l'aromatase pendant 5 ans (durée médiane de suivi : 6,9 ans)
The long-term risk of recurrence of hormone-receptor-positive breast cancer is well established. When competing risks of death are disregarded, there is an almost linear risk of recurrence over 20 years among women treated with 5 years of adjuvant endocrine therapy. In women treated with 5 years of adjuvant tamoxifen, additional extended endocrine therapy with either tamoxifen or an aromatase inhibitor results in clinically meaningful reductions in the risk of recurrence and death from breast cancer. However, until recently, little was known about the benefit of extending treatment in women who had received aromatase inhibitors within the first 5 years after diagnosis.
The Lancet Oncology , commentaire, 2017